NanOlogy registers first patient for Phase 2 NanoPac® Clinical Trial
Category: #healthcare  By Mateen Dalal  Date: 2020-11-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

NanOlogy registers first patient for Phase 2 NanoPac® Clinical Trial

NanOlogy LLC, a renowned clinical-stage oncology firm working on intratumoral therapy for solid tumors, has reportedly enrolled the very first patient for its Phase 2 clinical study of NanoPac, its intratumoral injection candidate to treat local prostate cancer.

The single-arm study is examining about 3 monthly injections of this drug in patients enrolled for prostatectomy about 90 days following the first injection. Patients would be monitored for tumor and safety response. The patients’ immune response would be gauged through flow cytometry and multiplex immunohistochemistry.

Craig G. Rogers, MD, clinical investigator for the trial from the Henry Ford Cancer Institute, stated that NanoPac finished its first in human clinical safety study earlier in 2019. Now, in the Phase 2 study, the firm would examine both the efficacy and safety of multiple intratumoral injections of NanoPac within patients suffering from prostate cancer.

Rogers further added that the company would also analyze blood and tissue for immune response as well as what therapeutic impact NanoPac may provide to patients diagnosed with this cancer. The Phase 2 trial is in line with the company’s vision to offer a precision medicine approach and cutting edge clinical studies at the Henry Ford Cancer Institute.

The multicenter Phase 2 study hopes to register about 18 patients suffering from localized prostate cancer who would undergo prostatectomy after three months of registration. During this trial, patients would get 3 monthly Nanopac intratumoral injections at a dose that determined based on lesion size.

The primary result measures would be tumor response, tolerability, and safety. Any patient’s tumor response would be evaluated based on change in tumor volume and dimension, PI-RADS compared to baseline, PSA, and PSA-density.

Along with the rapid ongoing clinical studies for prostate cancer, the company’s clinical programs are further advancing in several other genitourinary cancers such as dermal, lung, peritoneal, and gastrointestinal cancers.

Source credit: https://nanology.us/2020/11/04/nanology-enrolls-first-patient-in-phase-2-clinical-trial-of-nanopac-for-intratumoral-treatment-of-prostate-cancer/

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

AltPep Corporation raises USD 23.15 million in Series A funding round
AltPep Corporation raises USD 23.15 million in Series A funding round
By Mateen Dalal

According to reliable sources, U.S.-based privately held biomedical organization AltPep Corporation ...

Volvo to triple EV production volume at its Belgium facility from 2022
Volvo to triple EV production volume at its Belgium facility from 2022
By Mateen Dalal

Swedish luxury car manufacturer, Volvo AB has announced plans to triple electric vehicle production ...

Lenovo launches new AR smart glasses to improve industrial productivity
Lenovo launches new AR smart glasses to improve industrial productivity
By Mateen Dalal

In a bid to enhance efficiency among industrial workers amidst the alarming increase in distributed ...